Login
Companies $NGNE
$23.30 +$0.00 (0.0%) After hours
Neurogene Inc. logo

Neurogene Inc.

neurogene.com

What Do They Do?

Develops genetic medicines for people with rare neurological diseases, including gene therapy for Rett syndrome.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −39% (Loss)
vs −$21M in Q3 FY2025

From cancer immunotherapies to neurological gene therapies The older report described a focus on computationally designed cytokine mimetics for cancer and inflammatory conditions, with research suspended while strategic alternatives were considered. The latest report describes genetic medicines for rare neurological diseases, led by a Rett syndrome gene therapy program.

Who Do They Compete With?

Competes with Taysha Gene Therapies

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support